148 related articles for article (PubMed ID: 25504503)
1. Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2015 Mar; 43(3):353-7. PubMed ID: 25504503
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
3. Differential expression and function of CYP2C isoforms in human intestine and liver.
Läpple F; von Richter O; Fromm MF; Richter T; Thon KP; Wisser H; Griese EU; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2003 Sep; 13(9):565-75. PubMed ID: 12972955
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
5. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes.
Lundblad MS; Stark K; Eliasson E; Oliw E; Rane A
Biochem Biophys Res Commun; 2005 Feb; 327(4):1052-7. PubMed ID: 15652503
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of human cytochrome P450 enzymes from the CYP3A subfamily in the brains of alcoholic subjects and drug-free controls.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2013 Jun; 41(6):1187-94. PubMed ID: 23491640
[TBL] [Abstract][Full Text] [Related]
7. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
8. Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions.
Narimatsu S; Torigoe F; Tsuneto Y; Saito K; Hanioka N; Masuda K; Katsu T; Yamamoto S; Yamano S; Baba T; Miyata A
Biochem Pharmacol; 2006 Dec; 72(12):1738-48. PubMed ID: 17010942
[TBL] [Abstract][Full Text] [Related]
9. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
10. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver.
Hasegawa M; Tahara H; Inoue R; Kakuni M; Tateno C; Ushiki J
Drug Metab Dispos; 2012 Mar; 40(3):474-80. PubMed ID: 22126990
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.
Niwa T; Yamazaki H
Curr Drug Metab; 2012 Oct; 13(8):1145-59. PubMed ID: 22571484
[TBL] [Abstract][Full Text] [Related]
12. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.
Raucy JL; Mueller L; Duan K; Allen SW; Strom S; Lasker JM
J Pharmacol Exp Ther; 2002 Aug; 302(2):475-82. PubMed ID: 12130704
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.
Scheer N; Kapelyukh Y; Chatham L; Rode A; Buechel S; Wolf CR
Mol Pharmacol; 2012 Dec; 82(6):1022-9. PubMed ID: 22918969
[TBL] [Abstract][Full Text] [Related]
14. The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.
Polonikov A; Bykanova M; Ponomarenko I; Sirotina S; Bocharova A; Vagaytseva K; Stepanov V; Churnosov M; Bushueva O; Solodilova M; Shvetsov Y; Ivanov V
Clin Exp Hypertens; 2017; 39(4):306-311. PubMed ID: 28513222
[TBL] [Abstract][Full Text] [Related]
15. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
16. Analyses of CYP2C in porcine microsomes.
Skaanild MT; Friis C
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):487-92. PubMed ID: 18803635
[TBL] [Abstract][Full Text] [Related]
17. Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis.
Achour B; Barber J; Rostami-Hodjegan A
Drug Metab Dispos; 2014 Aug; 42(8):1349-56. PubMed ID: 24879845
[TBL] [Abstract][Full Text] [Related]
18. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
Polonikov A; Kharchenko A; Bykanova M; Sirotina S; Ponomarenko I; Bocharova A; Vagaytseva K; Stepanov V; Bushueva O; Churnosov M; Solodilova M
Gene; 2017 Sep; 627():451-459. PubMed ID: 28687336
[TBL] [Abstract][Full Text] [Related]
20. Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.
Kong TY; Kim JH; Choi WG; Lee JY; Kim HS; Kim JY; In MK; Lee HS
Anal Bioanal Chem; 2017 Feb; 409(6):1667-1680. PubMed ID: 27924364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
